172 related articles for article (PubMed ID: 19617799)
21. [Extranodal marginal zone lymphoma of the ocular adnexa].
Møller A; Specht L; Toft PB; Sjø LD
Ugeskr Laeger; 2008 Nov; 170(45):3660-3. PubMed ID: 18986616
[TBL] [Abstract][Full Text] [Related]
22. Intralesional interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results.
Blasi MA; Tiberti AC; Valente P; Laguardia M; Sammarco MG; Balestrazzi A; Larocca LM; Balestrazzi E
Ophthalmology; 2012 Mar; 119(3):494-500. PubMed ID: 22226154
[TBL] [Abstract][Full Text] [Related]
23. Intralesional Rituximab for the Treatment of Recurrent Ocular Adnexal Lymphoma.
Demirci H; Kauh CY; Rajaii F; Elner VM
Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S70-S71. PubMed ID: 26950471
[TBL] [Abstract][Full Text] [Related]
24. t(11;18)(q21;q21)-positive advanced-stage MALT lymphoma associated with monoclonal gammopathy: resistance to rituximab or rituximab-containing chemotherapy.
Ohno H; Isoda K
J Clin Exp Hematop; 2008 Nov; 48(2):47-54. PubMed ID: 19039196
[TBL] [Abstract][Full Text] [Related]
25. Spectral-domain optical coherence tomography of conjunctival mucosa-associated lymphoid tissue lymphoma with presumed choroidal involvement.
Williams BK; Tsui I; McCannel TA
Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1837-40. PubMed ID: 20532548
[TBL] [Abstract][Full Text] [Related]
26. Lymphoproliferative diseases of the ocular adnexa in Korea.
Oh DE; Kim YD
Arch Ophthalmol; 2007 Dec; 125(12):1668-73. PubMed ID: 18071120
[TBL] [Abstract][Full Text] [Related]
27. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
28. Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b.
Lachapelle KR; Rathee R; Kratky V; Dexter DF
Arch Ophthalmol; 2000 Feb; 118(2):284-5. PubMed ID: 10676800
[No Abstract] [Full Text] [Related]
29. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.
Valencak J; Weihsengruber F; Rappersberger K; Trautinger F; Chott A; Streubel B; Muellauer L; Der-Petrossian M; Jonak C; Binder M; Raderer M
Ann Oncol; 2009 Feb; 20(2):326-30. PubMed ID: 18836086
[TBL] [Abstract][Full Text] [Related]
30. [The preliminary observation of intralesional rituximab administration in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma].
Yang JP; Pang X; Zhang K; Wang LL; Zhu Y
Zhonghua Yan Ke Za Zhi; 2020 Nov; 56(11):839-845. PubMed ID: 33152842
[No Abstract] [Full Text] [Related]
31. Rituximab-induced remission of a gastric MALT lymphoma.
Datta YH; Kampalath B; Binion DG
Leuk Lymphoma; 2004 Jun; 45(6):1297-9. PubMed ID: 15360017
[TBL] [Abstract][Full Text] [Related]
32. Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa.
Annibali O; Chiodi F; Sarlo C; Cortes M; Quaranta-Leoni FM; Quattrocchi C; Bianchi A; Bonini S; Avvisati G
Biomed Res Int; 2015; 2015():895105. PubMed ID: 26425558
[TBL] [Abstract][Full Text] [Related]
33. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma).
Son SH; Choi BO; Kim GW; Yang SW; Hong YS; Choi IB; Kim YS
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):86-91. PubMed ID: 19632068
[TBL] [Abstract][Full Text] [Related]
34. Monthly administration of rituximab is useful for patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma.
Mino T; Mihara K; Yoshida T; Takihara Y; Ichinohe T
Blood Cancer J; 2014 Sep; 4(9):e245. PubMed ID: 25215661
[No Abstract] [Full Text] [Related]
35. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
36. Small-cell lung cancer arising after chemotherapy for a patient with lymphoma of pulmonary mucosa-associated lymphoid tissue-a case report.
Nakao M; Oguri T; Maeno K; Kusumoto S; Ota C; Takakuwa O; Uemura T; Ozasa H; Iwashima Y; Miyazaki M; Kutsuna T; Nakamura A; Inagaki H; Sato S; Ueda R
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1711-4. PubMed ID: 19838033
[TBL] [Abstract][Full Text] [Related]
37. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa.
Ferreri AJ; Ponzoni M; Martinelli G; Muti G; Guidoboni M; Dolcetti R; Doglioni C
Haematologica; 2005 Nov; 90(11):1578-9. PubMed ID: 16266908
[TBL] [Abstract][Full Text] [Related]
38. Intralesional interferon-α for the treatment of bilateral conjunctival mucosa-associated lymphoid tissue lymphoma.
Holds J; Buchanan A; Hanson R
Pediatr Blood Cancer; 2012 Jul; 59(1):176-8. PubMed ID: 21793177
[TBL] [Abstract][Full Text] [Related]
39. Second-line 90Yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab.
Oellers P; Savar A; Samaniego F; Pro B; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2012; 28(6):e145-6. PubMed ID: 22820440
[TBL] [Abstract][Full Text] [Related]
40. A lymphoid conjunctival tumor--clinical aspects; therapeutical options.
Apostol S; Filip M; Nechita A; Filip A
Oftalmologia; 2005; 49(1):26-9. PubMed ID: 15934333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]